The Company's first GalAhead™-based RNAi drug candidate, STP122G, has started a Phase I clinical trial in May 2023. The start of the trial indicates that Sirnaomics' proprietary GalNAc RNAi platform technology, GalAhead™, has the potential to help patients with high unmet needs in the areas of hematologic, cardiometabolic, immunologic and rare disorders.

Precision in Drug Discovery & Preclinical Summit Oral Presentation Details

• Presentation Title: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
• Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
• Time/Date: 2:55 pm-3:20 pm ET on Tuesday, Jun 13, 2023
• Location: Revere Hotel, Boston, USA

RNA Therapeutics USA Oral Presentation Details

• Presentation Title: GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple Genes
• Presenter: Jim Weterings, PhD, Sirnaomics Senior Director of Technology Innovation
• Time/Date: 3:10 pm-3:50 pm ET on Thursday, June 15, 2023
• Location: Horton Grand Hotel; San Diego, USA

19^th Drug Discovery Nexus Oral Presentation Details

• Presentation Title: GalAhead™: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
• Presenter: Jack Wei, PhD, Sirnaomics Senior Director of Drug Discovery
• Time/Date: 3:15 pm -3:40 pm ET on Friday, June 16, 2023
• Location: Holiday Inn Express – Arena Towers; Amsterdam, Netherlands